LT4331584T - Lanifibranoro deuterintų darinių terapietiniai naudojimai - Google Patents

Lanifibranoro deuterintų darinių terapietiniai naudojimai

Info

Publication number
LT4331584T
LT4331584T LTEP23201458.9T LT23201458T LT4331584T LT 4331584 T LT4331584 T LT 4331584T LT 23201458 T LT23201458 T LT 23201458T LT 4331584 T LT4331584 T LT 4331584T
Authority
LT
Lithuania
Prior art keywords
deuterine
lanifibranor
derivatives
therapeutic uses
therapeutic
Prior art date
Application number
LTEP23201458.9T
Other languages
English (en)
Inventor
Christian Montalbetti
Benaissa Boubia
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of LT4331584T publication Critical patent/LT4331584T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP23201458.9T 2018-07-27 2019-07-26 Lanifibranoro deuterintų darinių terapietiniai naudojimai LT4331584T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1857021A FR3084254B1 (fr) 2018-07-27 2018-07-27 Derives deuteres du lanifibranor

Publications (1)

Publication Number Publication Date
LT4331584T true LT4331584T (lt) 2025-03-25

Family

ID=63684156

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEPPCT/FR2019/051860T LT3830085T (lt) 2018-07-27 2019-07-26 Deuterinti lanifibranoro dariniai
LTEP23201458.9T LT4331584T (lt) 2018-07-27 2019-07-26 Lanifibranoro deuterintų darinių terapietiniai naudojimai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEPPCT/FR2019/051860T LT3830085T (lt) 2018-07-27 2019-07-26 Deuterinti lanifibranoro dariniai

Country Status (19)

Country Link
US (2) US12291526B2 (lt)
EP (2) EP4331584B1 (lt)
JP (2) JP7434278B2 (lt)
CN (1) CN112638911B (lt)
DK (2) DK4331584T3 (lt)
ES (2) ES2970597T3 (lt)
FI (2) FI3830085T3 (lt)
FR (1) FR3084254B1 (lt)
HR (2) HRP20250340T8 (lt)
HU (2) HUE070489T2 (lt)
LT (2) LT3830085T (lt)
MA (1) MA67726B1 (lt)
MD (1) MD4331584T2 (lt)
PL (2) PL4331584T3 (lt)
PT (2) PT3830085T (lt)
RS (2) RS65095B1 (lt)
SI (2) SI4331584T1 (lt)
SM (2) SMT202400053T1 (lt)
WO (1) WO2020021215A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102199640B1 (ko) * 2020-01-06 2021-01-07 브렉소젠 주식회사 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022143479A1 (zh) * 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
KR20240047402A (ko) * 2021-08-12 2024-04-12 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도
CN120857930A (zh) 2023-01-19 2025-10-28 伊文蒂瓦公司 拉尼兰诺制剂
KR20260020956A (ko) 2023-06-05 2026-02-12 엥방티바 간 질환을 가진 환자의 내장 혈관 확장증의 치료에 사용하기 위한 라니피브라노르
KR20260016549A (ko) 2023-06-06 2026-02-03 엥방티바 라니피브라노르를 이용한 간 질환 치료를 모니터링하기 위한 아디포넥틴, 페리틴, mmp9 및 트랜스페린의 용도
WO2024252162A1 (en) 2023-06-06 2024-12-12 Inventiva Use of ck18m65, hyaluronic acid, fructosamine and alt for monitoring of liver disease treatment with lanifibranor
WO2025061927A1 (en) 2023-09-22 2025-03-27 Inventiva Method of making lanifibranor
WO2025132989A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025132955A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
TW202543596A (zh) 2024-03-15 2025-11-16 法商因文帝華公司 預防接受過氧化物酶體增生劑活化受體(ppar)促效劑治療患者之血液病症
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
JP6557684B2 (ja) 2014-06-13 2019-08-07 インベンティバ 線維性疾患の治療に用いられるppar化合物
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
WO2018039521A1 (en) 2016-08-26 2018-03-01 Concert Pharmaceuticals, Inc. Deuterated cenicriviroc
US11504380B2 (en) * 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis

Also Published As

Publication number Publication date
FI3830085T3 (fi) 2024-01-17
DK3830085T3 (da) 2024-01-22
HUE065045T2 (hu) 2024-04-28
EP4331584B1 (fr) 2025-01-01
FR3084254B1 (fr) 2020-10-23
SI3830085T1 (sl) 2024-03-29
HRP20250340T8 (hr) 2025-06-20
DK4331584T3 (da) 2025-03-17
ES2970597T3 (es) 2024-05-29
CN112638911B (zh) 2024-07-19
SMT202400053T1 (it) 2024-03-13
HRP20250340T1 (hr) 2025-05-09
HRP20240157T1 (hr) 2024-04-12
FI4331584T3 (fi) 2025-04-01
JP7637281B2 (ja) 2025-02-27
WO2020021215A1 (fr) 2020-01-30
SMT202500113T1 (it) 2025-05-12
RS66614B1 (sr) 2025-04-30
ES3014955T3 (en) 2025-04-28
LT3830085T (lt) 2024-02-12
SI4331584T1 (sl) 2025-04-30
US20210300913A1 (en) 2021-09-30
US20250263406A1 (en) 2025-08-21
EP3830085B1 (fr) 2023-11-08
PL3830085T3 (pl) 2024-04-15
EP4331584A1 (fr) 2024-03-06
JP2021533101A (ja) 2021-12-02
EP3830085A1 (fr) 2021-06-09
US12291526B2 (en) 2025-05-06
CN112638911A (zh) 2021-04-09
PT3830085T (pt) 2024-01-24
HUE070489T2 (hu) 2025-06-28
RS65095B1 (sr) 2024-02-29
JP7434278B2 (ja) 2024-02-20
MA67726B1 (fr) 2025-04-30
FR3084254A1 (fr) 2020-01-31
PT4331584T (pt) 2025-02-27
PL4331584T3 (pl) 2025-04-28
MD4331584T2 (ro) 2025-11-30
JP2024036611A (ja) 2024-03-15

Similar Documents

Publication Publication Date Title
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
IL283134A (en) Alcohol-resistant drug formulations
MA50205A (fr) Formulation de nicotine
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
PL4393545T3 (pl) Nowe zastosowania pochodnych piperydynylo-indolowych
IL281927A (en) Combination therapy for melanoma
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
IL283069A (en) Methods for administering corticosteroids
PL3457851T3 (pl) Pochodne sobetiromu
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
IL282330A (en) Therapeutic compounds
DK3768669T3 (da) Piperazinazaspiroderivater
PL3570854T3 (pl) Zastosowanie terapeutyczne proszku z owadów
EP3752001A4 (en) SOBETIROMA DERIVATIVES
PL3625224T3 (pl) Pochodne n-podstawionego indolu
EP3860585A4 (en) Therapeutic compositions
LT3576740T (lt) Vėžio gydymas
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
LT3600315T (lt) Naujas terapinis h3 ligandų panaudojimas
DK3796975T3 (da) Sulfonylaminobenzamidderivater
IL285765A (en) Therapeutic uses of dulaglutide
PL3697399T3 (pl) Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg
IL289338A (en) Therapeutic interactions of leucomethylthioninium
EP3843748C0 (en) COMBINATION THERAPY